Home › NDC Lookup › Ingredients › Pseudoephedrine Hcl › 00904-5053-59
SudoGest Pseudoephedrine HCl 30 mg Tablet, Film Coated, 100-count — NDC 00904-5053-59 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

SudoGest Pseudoephedrine HCl 30 mg Tablet, Film Coated, 100-count — NDC 0904-5053-59 (Billing 00904-5053-59)

by Major Pharmaceuticals · 1 BOTTLE, PLASTIC in 1 CARTON / 100 TABLET, FILM COATED in 1 BOTTLE, PLASTIC

This is a package of 100 tablets of SudoGest Pseudoephedrine HCl 30 mg Tablet, Film Coated from Major Pharmaceuticals, marketed since Aug 1981 and currently FDA-listed; retail pharmacies pay about $0.0776 per tablet (NADAC). It is this product's only package size.

NDC 00904-5053-59
🏷️ FDA NDC (as labeled) 0904-5053-59 billing pads the labeler segment with a zero
OTC On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 0904-5053-59 alone.

Record
FDA NDC Directory package listing · Human OTC drug
Code segments
0904 labeler · 5053 product · 59 package
Package marketed since
Aug 25, 1981
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Billing quantity
100 EA per package
Barcode (UPC)
0309045053591
Medicaid fills, this package
57,456 prescriptions in the last four reported quarters
FDA record last changed
Jul 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0904-5053-59
Product NDC 0904-5053
11-digit billing NDC 00904505359
NCPDP billing unit EA — each (per item)
RxCUI 1049160, 1049162
UNII 6V9V2RYJ8N
UPC 0309045053591
Application # M012
SPL Set ID d46577aa-7fd7-2130-6ed6-4b3f7562491f
Established class (EPC) alpha-Adrenergic Agonist
Mechanism of action Adrenergic alpha-Agonists
DEA schedule Non-controlled
Marketing category OTC MONOGRAPH DRUG
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 1981-08-25
Route ORAL
Dosage form TABLET, FILM COATED
Substance PSEUDOEPHEDRINE HYDROCHLORIDE

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 42101020100305
GPI class SudoGest
GCN Seq No 005089
GCN 20481
HICL code 002091
Ingredient (HICL) Pseudoephedrine Hcl
HIC1 code B
Therapeutic class — broad (HIC1) Respiratory System
HIC2 code B6
Therapeutic class — intermediate (HIC2) Drugs Affecting The Trachea And Bronchi (Cont3)
HIC3 code B6V
Therapeutic class — specific (HIC3) Decongestants, Oral
AHFS code 12:12.12.00
AHFS class Alpha- And Beta-Adrenergic Agonists
FDB label name SUDOGEST 30 MG TABLET
FDB brand name Sudogest
Legend status O — Over-the-counter (OTC) drug or device
Quick answers
  • GSN (GCN sequence number): 005089
  • GCN: 20481
  • GPI-14 (Medi-Span): 42101020100305
  • HICL (First Databank): 002091
  • AHFS class code: 12:12.12.00
  • RxCUI (RxNorm): 1049160
Why two NDCs? The FDA registers this code as 0904-5053-59 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00904-5053-59. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the alpha-Adrenergic Agonist class.

Pharmacologic class alpha-Adrenergic Agonist
Drug family (ATC) Sympathomimetics
How it works Adrenergic alpha-Agonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name SUDOGEST 30 MG TABLET Ingredient Pseudoephedrine Hcl
📗 Our plain-language guide HelloPharmacist
  • It temporarily relieves nasal congestion from the common cold, hay fever or other upper respiratory allergies. Many products also relieve sinus congestion and pressure.
  • It depends on the product. Regular tablets and softgels are usually taken every 4 to 6 hours, while 12-hour extended-release tablets are taken every 12 hours. Check your box for th...
  • No. Swallow them whole. Don't divide, crush, chew or dissolve them. Seeing part of the tablet in your stool can happen and is normal.
  • Can I crush or chew the extended-release tablets?
📖 Read our full Pseudoephedrine guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.078 $7.76 / 100 tablets
Medicaid paysCMS SDUD · 12 mo $0.2687 $26.87 / 100 tablets
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per ea) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $0.078 $0.048
▲ Up 52% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
00904-5053-59 You're viewing this Main listing 1 BOTTLE, PLASTIC in 1 CARTON / 100 TABLET, FILM COATED in 1 BOTTLE, PLASTIC 1981-08-25 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Good Sense Nasal Decongestant 30 mg 00113-0432-62 L. 24 tablets $0.078 — Availability likely —
Nasal Decongestant 30 mg 00536-3607-35 Rugby 24 tablets $0.078 — Availability likely —
SudoGest 30 mgthis 00904-5053-59 Major 100 tablets $0.078 — Availability likely —
SudoGest Nasal Decongestant 30 mg 00904-6337-24 Major 1 tablet $0.078 — Availability likely —
SudoGest 30 mg 00904-6727-60 Major 100 tablets $0.078 — Availability likely —
Pseudoephedrine HCl 30 mg 00904-6990-61 Major 10 tablets $0.078 — Availability likely —
pseudoephedrine hydrochloride 30 mg 45802-0432-62 Padagis 1 tablet $0.078 — Availability likely —
Nasal Decongestant Maximum Strength, Non-Drowsy 30 mg 46122-0428-62 Amerisource 24 tablets $0.078 — Availability likely —
Leader Nasal Decongestant 30 mg 70000-0002-01 Cardinal 1 tablet $0.078 — Availability likely —
Nasal Decongestant Maximum Strength 30 mg 70677-1017-01 Strategic 24 tablets $0.078 — Availability likely —
Nasal Decongestant D 30 mg 00363-1214-08 Walgreen 24 tablets — — FDA listed —
Sinus Pressure and Congestion Relief Maximum Strength 30 mg 11822-0112-02 Rite 24 tablets — — FDA listed —
Nasal Decongestant Maximum Strength 30 mg 21130-0112-08 Better 24 tablets — — FDA listed —
sinus 30 mg 30142-0613-62 Kroger 1 tablet — — Discontinued —
Sinus Decongestion 30 mg 30142-0641-08 Kroger 24 tablets — — FDA listed —
Topcare Nasal Decongestant Maximum Strength Non Drowsy 30 mg 36800-0432-62 Topco 1 tablet — — FDA listed —
Nasal Decongestant 30 mg 37808-0112-22 H 24 tablets — — FDA listed —
equaline nasal decongestant non drowsy maximum strength 30 mg 41163-0432-67 United 6 tablets — — FDA listed —
nasal decongestant maximum strength non drowsy 30 mg 41250-0432-62 Meijer 1 tablet — — FDA listed —
CareOne Nasal and Sinus Decongestant 30 mg 41520-0881-62 American 12 tablets — — FDA listed —
Sinus and Congestion Non-Drowsy 30 mg 49035-0780-08 Wal-Mart 24 tablets — — FDA listed —
Sudogest 30 mg 50090-1961-00 A-S 28 tablets — — FDA listed —
Sudogest Nasal Decongestant 30 mg 50090-4345-00 A-S 48 tablets — — Discontinued —
pseudoephedrine hydrochloride 30 mg 50090-5615-01 A-S 1 tablet — — FDA listed —
SUDAFED Sinus Congestion 30 mg 50580-0363-01 Kenvue 12 tablets — — FDA listed —
Nasal Decongestant 30 mg 50844-0112-08 L.N.K. 12 tablets — — FDA listed —
Sinus and Nasal Decongestant 30 mg 51316-0121-22 CVS 24 tablets — — FDA listed —
Sinus And Nasal Decongestant 30 mg 51316-0317-62 CVS 12 tablets — — FDA listed —
Nasal Decongestant 30 mg 56062-0432-62 Publix 24 tablets — — FDA listed —
Nasal Decongestant Non-Drowsy 30 mg 59779-0112-08 CVS 24 tablets — — FDA listed —
Nasal Decongestant 30 mg 59779-0432-62 CVS 1 tablet — — FDA listed —
Nasal Decongestant 30 mg 63187-0344-24 Proficient 24 tablets — — FDA listed —
Nasal Decongestant Maximum Strength 30 mg 63868-0802-24 CHAIN 24 tablets — — FDA listed —
Nasal Decongestant Maximum Strength 30 mg 68016-0473-24 Chain 24 tablets — — FDA listed —
pseudoephedrine hydrochloride 30 mg 71205-0197-24 Proficient 1 tablet — — FDA listed —
Sinus Congestion 30 mg 83324-0054-24 Chain 24 tablets — — FDA listed —
pseudoephedrine hydrochloride 30 mg 85766-0049-24 Sportpharm 1 tablet — — FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
1981
On the market since
Aug 1981
📍
2026
Currently FDA-listed
45 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color red
ShapeRound
Imprint44;112
Size7 mm
ScoringNot scored
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Pseudoephedrine inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII M28OL1HH48
    Croscarmellose sodium is a plant-based substance derived from cellulose. It acts as a disintegrant, helping tablets and capsules break down quickly in the digestive system so the medicine can be absorbed.
  • UNII O7TSZ97GEP
    A mineral compound that serves as a filler and binding agent in tablets and capsules. It adds bulk to the medicine and helps hold ingredients together during manufacturing.
  • UNII 6T47AS764T
    Red 40 Lake is a synthetic colorant made by combining Red 40 dye with aluminum hydroxide. It's used to give tablets, capsules, and other medicines a red or pink color for identification and appearance.
  • UNII GYP6Z2JR6Q
    FD&C Yellow No. 6 Aluminum Lake is a yellow colorant made by combining FD&C Yellow No. 6 dye with aluminum salts. It's used to color tablets, capsules, and other medicines so they're easier to identify.
  • UNII 3NXW29V3WO
    Hypromellose is a plant-based thickener made from cellulose. It's used in medicines as a binder to hold ingredients together, a coating for tablets, and a thickener for liquids.
  • UNII 70097M6I30
    Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
  • UNII OP1R32D61U
    Microcrystalline cellulose is a purified form of cellulose, a natural fiber from plant sources. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and give the medicine its shape and size.
  • UNII VH2XOU12IE
    Polydextrose is a synthetic polymer made from dextrose (sugar) that acts as a bulking agent and filler in medicines. It helps give tablets and capsules proper volume and texture while often adding slight sweetness.
  • UNII 3WJQ0SDW1A
    Polyethylene glycol is a synthetic liquid or solid polymer used in medicines as a solvent, lubricant, and humectant. It helps dissolve active ingredients, reduces friction during manufacturing, and retains moisture in the final product.
  • UNII ETJ7Z6XBU4
    Silicon dioxide is a naturally occurring mineral used as a glidant and anti-caking agent. It helps powder ingredients flow smoothly and prevents clumping during manufacturing and storage.
  • UNII 15FIX9V2JP
    Titanium dioxide is a bright white mineral powder commonly used as a colorant and opacifying agent. It makes pills and tablets white or lighter in color and helps make coatings non-transparent.
  • UNII XHX3C3X673
    Triacetin is a clear, oily liquid made from glycerin and acetic acid. It works as a plasticizer and solvent in medicines, helping soften coatings and improve how liquids mix together in formulations.

12 inactive ingredients listed in the exact product block matched to this NDC.

The official label also statescroscarmellose sodium, dibasic calcium phosphate dihydrate, FD&C red #40 aluminum lake, FD&C yellow #6 aluminum lake, hypromellose, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, silicon dioxide, titanium dioxide, triacetin

Label-section wording can be broader than the structured product block and may mention additional formulation ingredients.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerMajor Pharmaceuticals
FDA applicationM012 (OTC MONOGRAPH DRUG)
Labeler code00904
First marketedAug 1981
Product typeHuman Otc Drug
Portfolio630 products on file

More NDCs from Major Pharmaceuticals labeler code 00904

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⚠️ Warnings 🧪 Active Ingredient 🧪 Inactive Ingredients 🎯 Purpose 📄 Do Not Use 📄 Ask a Doctor Before Use If 📄 When Using This Product 📄 Stop Use and Ask a Doctor If 🤰 If Pregnant or Breast-Feeding 📄 Keep Out of Reach of Children 📄 Questions or Comments 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 23 words ▾

Uses temporarily relieves nasal congestion due to the common cold, hay fever or other upper respiratory allergies temporarily relieves sinus congestion and pressure

⏱️ Dosage and Administration 57 words ▾

Directions adults and children 12 years and over take 2 tablets every 4 to 6 hours; do not take more than 8 tablets in 24 hours children ages 6 to 11 years take 1 tablet every 4 to 6 hours; do not take more than 4 tablets in 24 hours children under 6 years do not use

⚠️ Warnings 145 words ▾

Warnings Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric or emotional conditions, or Parkinson's disease), or for 2 weeks after stopping the MAOI drug. If you do not know if your prescription drug contains an MAOI, ask a doctor or pharmacist before taking this product. Ask a doctor before use if you have heart disease diabetes thyroid disease high blood pressure difficulty in urination due to enlargement of the prostate gland When using this product do not exceed recommended dosage.

Stop use and ask a doctor if nervousness, dizziness, or sleeplessness occur symptoms do not improve within 7 days or occur with fever If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.

🧪 Active Ingredient 9 words ▾

Active ingredient (in each tablet) Pseudoephedrine HCl 30 mg

🧪 Inactive Ingredients 31 words ▾

Inactive ingredients croscarmellose sodium, dibasic calcium phosphate dihydrate, FD&C red #40 aluminum lake, FD&C yellow #6 aluminum lake, hypromellose, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, silicon dioxide, titanium dioxide, triacetin

🎯 Purpose 3 words ▾

Purpose Nasal decongestant

📄 Do Not Use 55 words ▾

Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric or emotional conditions, or Parkinson's disease), or for 2 weeks after stopping the MAOI drug. If you do not know if your prescription drug contains an MAOI, ask a doctor or pharmacist before taking this product.

📄 Ask a Doctor Before Use If 26 words ▾

Ask a doctor before use if you have heart disease diabetes thyroid disease high blood pressure difficulty in urination due to enlargement of the prostate gland

📄 When Using This Product 9 words ▾

When using this product do not exceed recommended dosage.

📄 Stop Use and Ask a Doctor If 23 words ▾

Stop use and ask a doctor if nervousness, dizziness, or sleeplessness occur symptoms do not improve within 7 days or occur with fever

🤰 If Pregnant or Breast-Feeding 10 words ▾

If pregnant or breast-feeding, ask a health professional before use.

📄 Keep Out of Reach of Children 21 words ▾

Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.

📄 Questions or Comments 4 words ▾

Questions or comments? 1-800-426-9391

📄 Package Label / Principal Display Panel 100 words ▾

Principal Display Panel NDC 0904-5053-59 MAJOR ® compare to the active ingredient in Sudafed ® Sinus Congestion* maximum strength SudoGest™ pseudoephedrine HCl 30 mg nasal decongestant relieves: sinus pressure, sinus congestion 100 tablets FOR PHARMACY USE ONLY. NOT FOR RETAIL SALE. actual size TAMPER EVIDENT: DO NOT USE IF IMPRINTED SAFETY SEAL UNDER CAP IS BROKEN OR MISSING Rev. 10/25 M-17 Re-order No.

700321 *This product is not manufactured or distributed by Kenvue Inc., owner of the registered trademark Sudafed ® Sinus Congestion. 50844 REV0619P11212 Distributed by: MAJOR ® PHARMACEUTICALS Indianapolis, IN 46268 (800) 616-2471 www.major-rugby.com Major 44-112 Major 44-112

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
57.5K
Units reimbursed last 4 qtrs
2.3M
Gross reimbursed last 4 qtrs
$608.9K
Avg / prescription
$10.60
Avg / unit
$0.2687
Latest quarter Q1 2026
12.4KRx
Medicaid pays / ea
$0.2687
gross reimbursed
vs
NADAC / ea
$0.0776
acquisition cost
=
Spread
+$0.1911
+246% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
62% FFS 38% MCO
Fee-for-service · 35,640 Rx Managed care · 21,816 Rx
State Medicaid map
Alaska: no data reported AK Maine: 4,639 units · 333 per 100k residents ME Washington: 94,354 units · 1,208 per 100k residents WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 11,143 units · 194 per 100k residents MN Wisconsin: 13,469 units · 228 per 100k residents WI Michigan: 4,209 units · 41.9 per 100k residents MI New York: 916,380 units · 4,682 per 100k residents NY Vermont: no data reported VT New Hampshire: 885 units · 63.1 per 100k residents NH Oregon: 263,007 units · 6,213 per 100k residents OR Nevada: 11,071 units · 347 per 100k residents NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: 6,109 units · 190 per 100k residents IA Illinois: 4,702 units · 37.5 per 100k residents IL Indiana: 496 units · 7.2 per 100k residents IN Ohio: 66,096 units · 561 per 100k residents OH Pennsylvania: 71,004 units · 548 per 100k residents PA New Jersey: 32,019 units · 345 per 100k residents NJ Massachusetts: 17,851 units · 255 per 100k residents MA California: 371,779 units · 954 per 100k residents CA Utah: 1,020 units · 29.9 per 100k residents UT Colorado: no data reported CO Nebraska: 25,267 units · 1,277 per 100k residents NE Missouri: no data reported MO Kentucky: 220,517 units · 4,872 per 100k residents KY West Virginia: 1,720 units · 97.2 per 100k residents WV Virginia: 24,814 units · 285 per 100k residents VA Maryland: 4,242 units · 68.6 per 100k residents MD Connecticut: no data reported CT Rhode Island: 2,138 units · 195 per 100k residents RI Arizona: 27,252 units · 367 per 100k residents AZ New Mexico: 3,475 units · 164 per 100k residents NM Kansas: 3,756 units · 128 per 100k residents KS Arkansas: no data reported AR Tennessee: 5,255 units · 73.7 per 100k residents TN North Carolina: no data reported NC South Carolina: 786 units · 14.6 per 100k residents SC Delaware: 3,955 units · 384 per 100k residents DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: 26,343 units · 896 per 100k residents MS Alabama: no data reported AL Georgia: 754 units · 6.8 per 100k residents GA D.C.: no data reported DC Hawaii: 14,051 units · 979 per 100k residents HI Texas: 11,762 units · 38.6 per 100k residents TX Florida: no data reported FL
Units reimbursed · per 100k residents
6.86,213
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Oregon 6,213 /100k
2 Kentucky 4,872 /100k
3 New York 4,682 /100k
4 Nebraska 1,277 /100k
5 Washington 1,208 /100k
6 Hawaii 979 /100k
7 California 954 /100k
8 Mississippi 896 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for SudoGest (this brand).

Top reported reactions

Systemic Lupus Erythematosus5,337
Pain5,307
Pemphigus5,214
Rheumatoid Arthritis5,213
Abdominal Discomfort5,117
Alopecia5,011
Glossodynia4,787

Reporter sex

10,900 reports
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 1,961 308
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
← 00904-4274-51 · Major 00904-5154-60 · Major →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.